Uğur Şahin, BioNTech CEO (Sebastian Gollnow/picture-alliance/dpa/AP Images)
BioNTech grabs PD-L1/VEGF bispecific with $55M upfront, expanding pipeline while lowering Covid guidance
As BioNTech continues to beef up its oncology pipeline, it’s once again turning to a Chinese partner.
The German biotech is putting down $55 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
